兆科眼科(06622.HK)料首款仿製藥最快明年商業化
兆科眼科(06622.HK)董事會主席兼行政總裁李小羿指,中國眼科藥物市場未來十年將迎來高速增長時期,退化性黃斑病、乾眼症等病症治療率低,預期擁有龐大發展空間。
公司預期2022年前推出三種仿製藥,並計劃未來三年提交九種仿製候選藥物的簡化新藥申請。他透露,用於治療青光眼的仿製藥,新藥申請預期於今年底可獲批,最快明年商業化。
兆科去年度虧損7.26億元人民幣,首席財務官馮新彥預期仿製藥商業化後將開始錄得收入,但由於仿製藥價格較低,相信要自主研發的創新藥商業化後,財務水平才會出現根本性轉折點。
是次上市引入新加坡政府投資公司、高瓴、TPG、奧博資本及愛爾眼科醫院等基投,她表示,將探索在研發及商業化階段的合作可能性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.